TY - JOUR
T1 - Ibritumomab tiuxetan for non-Hodgkin's lymphoma
AU - Johnston, Patrick Bruce
AU - Bondly, Cara
AU - Micallef, Ivana
PY - 2006/1/1
Y1 - 2006/1/1
N2 - Targeted radiation therapy, or radioimmunotherapy, has been an important recent advancement in the treatment of patients with B-cell non-Hodgkin's lymphoma (NHL). 90Y ibritumomab tiuxetan comprises the murine monoclonal antibody ibritumomab, the linker chelator tiuxetan and the radiolabeled isotope 90yttrium. 90Y ibritumomab tiuxetan has been demonstrated to be efficacious in the treatment of B-cell NHL. Initial Phase I/II trials established the therapeutic dose of ibritumomab tiuxetan for low-grade NHL to be 0.4 mCi/kg, or 0.3 mCi/kg for patients with mild thrombocytopenia. Currently, there are many ongoing trials of ibritumomab tiuxetan with different dose schedules and intensities, in combination with chemotherapy and with stem cell transplantation, in an attempt to improve response rate and duration and to study its effectiveness in other B-cell lymphomas, including diffuse large B-cell lymphoma and mantle cell lymphoma. Radioimmunotherapy has great promise and the safe incorporation of 90Y ibritumomab tiuxetan into treatment will hopefully result in improved survival for patients with NHL.
AB - Targeted radiation therapy, or radioimmunotherapy, has been an important recent advancement in the treatment of patients with B-cell non-Hodgkin's lymphoma (NHL). 90Y ibritumomab tiuxetan comprises the murine monoclonal antibody ibritumomab, the linker chelator tiuxetan and the radiolabeled isotope 90yttrium. 90Y ibritumomab tiuxetan has been demonstrated to be efficacious in the treatment of B-cell NHL. Initial Phase I/II trials established the therapeutic dose of ibritumomab tiuxetan for low-grade NHL to be 0.4 mCi/kg, or 0.3 mCi/kg for patients with mild thrombocytopenia. Currently, there are many ongoing trials of ibritumomab tiuxetan with different dose schedules and intensities, in combination with chemotherapy and with stem cell transplantation, in an attempt to improve response rate and duration and to study its effectiveness in other B-cell lymphomas, including diffuse large B-cell lymphoma and mantle cell lymphoma. Radioimmunotherapy has great promise and the safe incorporation of 90Y ibritumomab tiuxetan into treatment will hopefully result in improved survival for patients with NHL.
KW - CD20
KW - Lymphoma
KW - Radioimmunotherapy
KW - Targeted irradiation
KW - Zevalin®
UR - http://www.scopus.com/inward/record.url?scp=85047697215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047697215&partnerID=8YFLogxK
U2 - 10.1586/14737140.6.6.861
DO - 10.1586/14737140.6.6.861
M3 - Article
C2 - 16761929
AN - SCOPUS:85047697215
SN - 1473-7140
VL - 6
SP - 861
EP - 869
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
IS - 6
ER -